SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A) announced an agreement
with Incyte that will bring together Agilent's expertise in the development of
companion diagnostics to support the development and commercialization of
Incyte's hematology and oncology portfolio. The agreement will enable Agilent to
continue to expand its companion diagnostics portfolio with biomarkers and
Incyte to leverage Agilent's expertise in IVD assay development, global
regulatory approvals, and commercialization to support clinical trials as well
as the potential registration and commercialization of CDx in the United States
and Europe.

Paul Beresford, general manager of Agilent's Companion Diagnostics Division,
said:
'By working together, Agilent and Incyte hope to expedite the development of
innovative precision medicine products, potentially paving the way for enhanced
patient health outcomes.'

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX